0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

AUREOMYCIN THERAPY IN LYMPHOGRANULOMA VENEREUM

ARCHIBALD FLETCHER, M.D.; M. MICHAEL SIGEL, Ph.D.; H. A. ZINTEL, M.D.
AMA Arch Surg. 1951;62(2):239-250. doi:10.1001/archsurg.1951.01250030244006.
Text Size: A A A
Published online

AFTER the definition of lymphogranuloma venereum as a clinical entity in 19131 and the development of a diagnostic skin test in 1925,2 the disease received wide recognition and numerous therapeutic agents were used in attempts to cure it. Indifferent results were obtained until the advent of sulfanilamide, which proved encouraging in the experience of early investigators.3 Although later reports of the cumulative experience were less optimistic,4 administration of the sulfonamides remained the treatment of choice, since some virustatic properties were demonstrated and secondary infection was controlled. Penicillin showed slight promise,4a, d and streptomycin has had little clinical trial.

The discovery of aureomycin5 and the demonstration of its activity against rickettsias and certain virus infections6 led to the early clinical trial of this agent in the treatment of lymphogranuloma venereum by Wright and his associates.7 They reported the early results in the treatment

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();